Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE)

Affiliations

• ¹ Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD, USA. Electronic address: [email protected].
• ² Department of Biostatistics, School of Medicine, Harvard University, Boston, MA, USA.
• ³ Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.
• ⁴ Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ⁵ Department of Urology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.
• ⁶ Northshore Medical Group, Glenview, IL, USA.
• ⁷ Department of Urology, University of Florida School of Medicine, Gainesville, FL, USA.
• ⁸ Division of Urology, University of Texas Medical Branch, Galveston, TX, USA.
• ⁹ Catherine and Joseph Aresty Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
• ¹⁰ Department of Urology, University of Iowa, Iowa City, IA, USA.
• ¹¹ Department of Urology, UCSF School of Medicine, San Francisco, CA, USA.
• ¹² Department of Urology, LSU Health Science Center, New Orleans, LA, USA.
• ¹³ Department of Social Sciences and Health Policy, School of Medicine, Wake Forest University, Winston-Salem, NC, USA.
• ¹⁴ Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.